You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anaplastic Lymphoma Kinase

Showing 1 - 25 of 7,571
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer, NSCLC Trial (Lorlatinib, Cisplatin or Carboplatin, Pemetrexed)

Not yet recruiting
  • Lung Cancer
  • Non-small Cell Lung Cancer
  • (no location specified)
Jul 7, 2023

NSCLC Stage IV, ALK Fusion Protein Expression Trial (Peptide vaccine)

Not yet recruiting
  • NSCLC Stage IV
  • ALK Fusion Protein Expression
  • Peptide vaccine
  • (no location specified)
Jul 21, 2023

free Survival and Evaluate Participant Experience for Metastatic

Active, not recruiting
  • Anaplastic Lymphoma Kinase-positive
  • Carcinoma Non-small-cell Lung
  • Maynard, Massachusetts
    EmpiraMed, Inc.
Feb 28, 2022

NSCLC Trial in Tianjin (Ensartinib, Placebo)

Recruiting
  • Non-small Cell Lung Cancer
  • Tianjin, China
    TianJin Medical University Cancer Institute & Hospital
Jul 13, 2022

NSCLC Trial in Shanghai (WX-0593)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, China
    Shanghai Jiao Tong University Chest Hospital
Mar 24, 2023

Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer

Active, not recruiting
  • Non-Small-Cell Lung Carcinoma
  • New York, New York
    Pfizer Inc
Apr 12, 2022

Anaplastic Lymphoma Kinase Gene Translocation, NSCLC Trial in Boston

Recruiting
  • Anaplastic Lymphoma Kinase Gene Translocation
  • Non-Small Cell Lung Cancer
    • Boston, Massachusetts
      Massachusetts General Hospital Cancer Center
    Jan 14, 2022

    Usage of Brigatinib in Treatment of Adult Approved Indications

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • Anaplastic Lymphoma Kinase
    • No Intervention
    • Busan, Korea, Republic of
      Pusan National University Hospital
    Oct 19, 2022

    A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

    Recruiting
    • Carcinoma, Non-Small-Cell Lung
    • +2 more
    • Beijing, Beijing, China
      Department of Respiratory and Critical Care Medicine, Peking Uni
    Aug 10, 2022

    NSCLC Trial in Germany (Brigatinib, Tyrosine kinase inhibitor)

    Recruiting
    • NSCLC
    • Berlin, Germany
    • +25 more
    Nov 10, 2022

    Lymphoma, Large-Cell, Anaplastic, NSCLC Trial (Brigatinib)

    Completed
    Has Results
    • Lymphoma, Large-Cell, Anaplastic
    • Carcinoma, Non-Small-Cell Lung
    • (no location specified)
    Jul 26, 2021

    NSCLC Trial (Zimberelimab, Domvanalimab, Pembrolizumab)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • (no location specified)
    Aug 12, 2022

    Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement Trial in Boston (Lorlatinib, Crizotinib,

    Recruiting
    • Lung Cancer
    • +6 more
    • Boston, Massachusetts
    • +1 more
    Mar 7, 2021

    Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma, Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma

    Recruiting
    • Relapsed Plasmablastic Lymphoma
    • +2 more
    • Belantamab Mafodotin
    • Boston, Massachusetts
    • +2 more
    Sep 20, 2021

    NSCLC Trial in Chang Chun (XZP-3621, Crizotinib)

    Not yet recruiting
    • Non-small Cell Lung Cancer
    • Chang Chun, Ji Lin, China
      Jilin Province Cancer Hospital
    Jan 10, 2022

    Alectinib in Anaplastic Lymphoma Kinase-Positive, Locally

    Completed
    • Non-Small Cell Lung Cancer
    • Busan, Korea, Republic of
    • +36 more
    Nov 17, 2022

    Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK) Trial in Sunto-gun, Koto, Fukuoka (LDK378)

    Completed
    • Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)
    • Sunto-gun, Shizuoka, Japan
    • +2 more
    Dec 16, 2020

    Locally Advanced Solid Tumor, Metastatic Solid Tumor Trial in United States (NVL-655)

    Recruiting
    • Locally Advanced Solid Tumor
    • Metastatic Solid Tumor
    • Orange, California
    • +13 more
    Jan 31, 2023

    Tumors Malignant Trial in Worldwide (Crizotinib)

    Active, not recruiting
    • Neoplasms Malignant
    • Fayetteville, Arkansas
    • +20 more
    Oct 5, 2021

    ALK or ROS1-positive NSCLC Trial in China (Crizotinib)

    Active, not recruiting
    • ALK or ROS1-positive NSCLC
    • Fuzhou, Fujian, China
    • +9 more
    Aug 30, 2022

    Circular RNAs in ALKpositive Anaplastic Large-cell Lymphoma

    Active, not recruiting
    • ALK-Positive Anaplastic Large Cell Lymphoma
    • RNAseq
    • Toulouse, France
      IUCT-Oncopole University Hospital
    Jul 3, 2023

    NSCLC Trial (Brigatinib)

    Completed
    Has Results
    • Carcinoma, Non-Small-Cell Lung
    • (no location specified)
    Feb 18, 2021

    Carcinoma, Non-Small-Cell Lung Trial in Worldwide (Lorlatinib)

    Recruiting
    • Carcinoma
    • Non-Small-Cell Lung
    • Orange, California
    • +31 more
    Dec 6, 2022

    NSCLC (NSCLC) Trial in Boston (Lorlatinib)

    Recruiting
    • Non-Small Cell Lung Cancer (NSCLC)
    • Boston, Massachusetts
      Massachusetts general Hospital
    Mar 7, 2021

    NSCLC ALK-positive, NSCLC c-Met Dependent, NSCLC ROS Marker Positive Trial in Worldwide (PF-02341066, Rifampin, Itraconazole)

    Completed
    Has Results
    • Non-Small Cell Lung Cancer ALK-positive
    • +4 more
    • Orange, California
    • +28 more
    Feb 15, 2022